KDR and neoplasm: ,21 Anti-­angiogenic therapy functions through targeting vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) signaling within the tumor microenvironment to induce vascular normalization pathways in the tumor microenvironment to normalize tumor blood vessels.22